PubRank

M P Kieny

Author PubWeight™ 111.59‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature 1987 5.45
2 New versatile cloning and sequencing vectors based on bacteriophage M13. Gene 1983 4.55
3 Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984 3.32
4 Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A 1991 3.22
5 Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol 1989 3.05
6 Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A 1984 2.85
7 Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1992 2.67
8 Linker tailing: unphosphorylated linker oligonucleotides for joining DNA termini. DNA 1984 2.56
9 Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. AIDS Res Hum Retroviruses 1993 2.22
10 HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med 1995 1.99
11 A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol 1991 1.72
12 Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992 1.71
13 Mutational analysis of the HIV nef protein. Virology 1990 1.68
14 Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells. AIDS Res Hum Retroviruses 1993 1.67
15 A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses 1995 1.56
16 Tumour prevention and rejection with recombinant vaccinia. Nature 1987 1.47
17 Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature 1986 1.45
18 Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis. J Clin Invest 1992 1.43
19 Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV-1 by deletion of the env amino-terminal signal sequence. Eur J Immunol 1990 1.40
20 Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 1999 1.38
21 Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene 1991 1.32
22 Loss of CD4 membrane expression and CD4 mRNA during acute human immunodeficiency virus replication. J Exp Med 1988 1.31
23 Ethical considerations related to the provision of care and treatment in vaccine trials. Vaccine 2007 1.30
24 Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol 1995 1.25
25 Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7alpha-hydroxy dehydroepiandrosterone and 7alpha-hydroxy pregnenolone. Proc Natl Acad Sci U S A 1997 1.25
26 Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus. AIDS Res Hum Retroviruses 1992 1.19
27 Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa. J Virol 1996 1.14
28 Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991 1.14
29 MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 2000 1.10
30 Use of recombinant vaccinia-rabies virus for oral vaccination of fox cubs (Vulpes vulpes, L) against rabies. Vet Microbiol 1988 1.07
31 Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1. AIDS Res Hum Retroviruses 1997 1.07
32 Isotypic restriction of the antibody response to human immunodeficiency virus. AIDS Res Hum Retroviruses 1988 1.07
33 HIV-1 core proteins expressed from recombinant vaccinia viruses. AIDS Res Hum Retroviruses 1989 1.06
34 Characterization of polyoma virus early proteins expressed from vaccinia virus recombinants. Gene 1988 1.04
35 Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. J Immunol 1993 1.02
36 Production of cholera toxin B subunit in Lactobacillus. FEMS Microbiol Lett 1998 1.00
37 Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species. J Wildl Dis 1989 1.00
38 DNA binding factors that bind to the negative regulatory element of the human immunodeficiency virus-1: regulation by nef. J Acquir Immune Defic Syndr 1990 0.98
39 Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 2005 0.98
40 Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996 0.98
41 High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes from HIV-1 Lai. Virology 1996 0.97
42 Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2001 0.94
43 Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacDeltanef. J Virol 2001 0.93
44 Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development. Vaccine 1990 0.91
45 Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J Immunother Emphasis Tumor Immunol 1993 0.91
46 HCV core, NS3, NS5A and NS5B proteins modulate cell proliferation independently from p53 expression in hepatocarcinoma cell lines. Arch Virol 2003 0.91
47 An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. AIDS 1990 0.89
48 Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein. AIDS Res Hum Retroviruses 1990 0.89
49 Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses. AIDS Res Hum Retroviruses 1989 0.88
50 Malaria vaccine development: progress and challenges. Curr Mol Med 2006 0.87
51 Molecular cloning and tissue distribution of a 26-kilodalton Schistosoma mansoni glutathione S-transferase. Mol Biochem Parasitol 1990 0.87
52 Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain. J Virol 1993 0.86
53 Technology transfer hub for pandemic influenza vaccine. Vaccine 2008 0.86
54 Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci U S A 1990 0.86
55 Production of a non-functional nef protein in human immunodeficiency virus type 1-infected CEM cells. J Gen Virol 1990 0.86
56 Isolation of recombinant partial gag gene product p18 (HIV-1Bru) from Escherichia coli. J Chromatogr 1989 0.86
57 First field trial of fox vaccination against rabies using a vaccinia-rabies recombinant virus. Vet Rec 1988 0.86
58 Primary multiplication site of the vaccinia-rabies glycoprotein recombinant virus administered to foxes by the oral route. J Gen Virol 1990 0.85
59 The HIV Nef protein: facts and hypotheses. Res Virol 1992 0.85
60 [HIV envelope proteins are bound by human epidermal Langerhans cells by a binding site which differs from the site on the CD4 molecule, and are internalized by receptor endocytosis]. C R Acad Sci III 1989 0.83
61 M13 bacteriophage vectors for the expression of foreign proteins in Escherichia coli: the rabies glycoprotein. J Mol Appl Genet 1984 0.83
62 Trypsin-resistant gp120 receptors are upregulated on short-term cultured human epidermal Langerhans cells. Res Virol 1991 0.83
63 Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. J Immunother Emphasis Tumor Immunol 1994 0.82
64 Antiplatelet antibodies during the course of HIV-preventive vaccine trial. AIDS 1996 0.81
65 HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins. AIDS Res Hum Retroviruses 1992 0.81
66 Lack of evidence for an immunosuppressive role for MUC1. Cancer Immunol Immunother 1999 0.81
67 Vaccinia recombinants expressing secreted and transmembrane forms of breast cancer-associated epithelial tumour antigen (ETA). Vaccine 1991 0.80
68 Immunogenicity of HILDA/LIF either in a soluble or in a membrane anchored form expressed in vivo by recombinant vaccinia viruses. Scand J Immunol 1993 0.80
69 Interaction of human epidermal Langerhans cells with HIV-1 viral envelope proteins (gp 120 and gp 160s) involves a receptor-mediated endocytosis independent of the CD4 T4A epitope. J Dermatol 1991 0.80
70 Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment. Hum Gene Ther 2000 0.80
71 Kex2p: a model for cellular endoprotease processing human immunodeficiency virus type 1 envelope glycoprotein precursor. Eur J Biochem 1994 0.79
72 Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization. J Virol 1994 0.79
73 Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody. Cancer Gene Ther 2000 0.79
74 Recombinant cholera toxin B subunit in Escherichia coli: high-level secretion, purification, and characterization. Protein Expr Purif 1994 0.79
75 Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses 1995 0.79
76 Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins. AIDS Res Hum Retroviruses 1991 0.78
77 The E2 trans-activating protein of bovine papillomavirus type 1 (BPV1) is serine-phosphorylated in vivo. Oncogene 1989 0.78
78 Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth. Cancer Gene Ther 2001 0.78
79 Use of vaccinia rabies recombinant for oral vaccination of wildlife. Vet Microbiol 1990 0.78
80 Cloned antigens and antiidiotypes. Hybridoma 1995 0.78
81 Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer. Cell Biophys 1994 0.78
82 An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step. Virology 2000 0.77
83 Directed cytokine expression in tumour cells in vivo using recombinant vaccinia virus. Ther Immunol 1994 0.77
84 Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice. Mol Immunol 1995 0.77
85 Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines. AIDS Res Hum Retroviruses 1997 0.76
86 Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins. Vaccine 1995 0.76
87 HIV-specific T lymphocyte immunity in mice immunized with a recombinant vaccinia virus. Eur J Immunol 1988 0.76
88 Immunogenicity of HIV-1LAI gp160 and env peptides in squirrel monkey Saimiri sciureus using alumine and experimental adjuvants. Clin Exp Immunol 1996 0.76
89 Vaccines for parasitic diseases. Curr Drug Targets Infect Disord 2001 0.76
90 Recombinant polyoma--vaccinia viruses: T antigen expression vectors and anti-tumor immunization agents. Biochimie 1988 0.76
91 Interaction between rabies infection and oral administration of vaccinia-rabies recombinant virus to foxes (Vulpes vulpes). J Gen Virol 1989 0.76
92 A novel transgenic mouse model for the in vivo evaluation of anti-human immunodeficiency virus type 1 drugs. AIDS Res Hum Retroviruses 1992 0.76
93 Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. 1984. Biotechnology 1992 0.75
94 Sulphation of hirudin in BHK cells. FEBS Lett 1990 0.75
95 Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1)--II. Synthetic peptides linked to HIV-1 carrier proteins gag and nef. Mol Immunol 1991 0.75
96 In vitro binding and internalization of HIV envelope glycoproteins by human epidermal Langerhans cells does not require the CD4-gp120-binding site. Res Virol 1990 0.75
97 [Experience with antirabies vaccination of foxes using the oral route coordinated among several European countries and perspectives on the use of recombinant vaccinia-rabies virus]. Parassitologia 1989 0.75
98 [Experimental vaccination against HIV-1 protects the chimpanzee against challenge with injections of infected lymphocytes]. Bull Acad Natl Med 1992 0.75
99 Multiple cytotoxic effector cells are induced by infection with the human immunodeficiency virus. Res Immunol 1989 0.75
100 In vivo delivery of interleukin-6 using vaccinia virus: effects on T lymphocytes in nude mice. Eur Cytokine Netw 1991 0.75
101 Strain specificity of cell-mediated cytotoxic responses specific for the human immunodeficiency virus type 1 (HIV-1) envelope protein in seropositive donors: HIV-1Lai is more commonly recognized than HIV-1MN. J Infect Dis 1994 0.75
102 Attempt to vaccinate orally harbour seals against phocid distemper. Vet Rec 1991 0.75
103 Meningococcal meningitis. Nat Rev Microbiol 2005 0.75